BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA1 associated protein 1 gene (BAP1) in the development of MMe. In this study, the chemosensitivity of human mesothelioma cell lines carrying BAP1 wild-type (WT), mutant and silenced was analysed. The BAP1 mutant cells were significantly less sensitive than BAP1 WT cell lines to the clinically relevant drug gemcitabine. Silencing of BAP1 significantly increased resistance of MMe cells to gemcitabine. Cell cycle analysis suggested that gemcitabine induced Sub-G1 phase accumulation of the BAP1 WT cells and increased in the S-phase in both BAP1 WT and mutant cells. Analysis of the role of BAP1 in apoptosis suggested that gemcitabine induced early apoptosis in both BAP1 WT and BAP1 mutant cells but with a much higher degree in the WT cells. Effects on the population of cells in late apoptosis, which can mark necrosis and necroptosis, could not be seen in the mutant cells, highlighting the possibility that BAP1 plays a role in several types of cell death. Significantly decreased DNA damage in the form of double-strand breaks was observed in gemcitabine-treated BAP1 mutant cells, compared to BAP1 WT cells under the same conditions. After BAP1 silencing, a significant decrease in DNA damage in the form of double-strand breaks was observed compared to cells transfected with scramble siRNA. Taken together, the results presented in this manuscript shed light on the role of BAP1 in the response of MMe cells to gemcitabine treatment and in particular in the control of the DNA damage response, therefore providing a potential route for more efficient MMe therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1
Machida, Y. J., Machida, Y., Vashisht, A. A., Wohlschlegel, J. A., & Dutta, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046755 · Cited by 274 · cited 1×
“BAP1/HCF-1 interaction is important for growth suppression in renal cancer; however, whether this is through BAP1-mediated deubiquitination and alteration of HCF-1 protein stability remains unclear [13,20].”
BackgroundGermline BAP1 mutations induce a Warburg effect
Bononi, A., Yang, H., Giorgi, C., Patergnani, S., Pellegrini, L., Su, M., Xie, G., Signorato, V., Pastorino, S., Morris, P., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.95 · Cited by 133
BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response
Dai, F., Lee, H., Zhang, Y., Zhuang, L., Yao, H., Xi, Y., Xiao, Z.-D., You, M. J., Li, W., Su, X., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619588114 · Cited by 94 · cited 1×
“However, BAP1 was also reported to inhibit apoptosis induced as a result of glucose deprivation, highlighting the complexity of the function this protein plays in determining cell fate [49,50].”
Background
Cited by
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
“Similarly, mesothelioma cells expressing wild-type BAP1 were more sensitive to gemcitabine-induced apoptosis and cell-cycle derangement, compared with mesothelioma cells expressing nonfunctional BAP1 or silenced for BAP1 (128).”
BackgroundERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Self-citationCarbone, M., Pass, H. I., Ak, G., Alexander, H. R., Baas, P., Baumann, F., Blakely, A. M., Bueno, R., Bzura, A., Cardillo, G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.014 · Cited by 97
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83
Metadata
- Authors
- Guazzelli, A., Meysami, P., Bakker, E., Demonacos, C., Giordano, A., Krstic-Demonacos, M., & Mutti, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-19
- Volume
- 20
- Issue
- 2
- Pages
- 429
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2909210318
- Cited by
- 56
- References
- 5
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.